Qure.ai has announced the appointment of Dr. Javier J. Zulueta as its new Chief Medical Officer (CMO), Pulmonology. Dr. Zulueta, a renowned expert in lung cancer screening and pulmonary medicine, previously served as Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, and as Pulmonary Division Chief at Mount Sinai Morningside Hospital.
In his new role, Dr. Zulueta will integrate his extensive clinical expertise with Qure.ai’s research and development in AI-driven lung health and digital care coordination. This appointment is expected to strengthen Qure.ai’s expansion across the USA and Europe.
Prashant Warier, Founder and CEO of Qure.ai, said, “We are delighted to welcome Dr. Zulueta. His unmatched global experience in lung cancer screening and management will play a pivotal role in enhancing our AI-powered Lung Cancer Suite and driving large-scale clinical adoption in health systems worldwide.”
Dr. Zulueta added, “Lung cancer is the deadliest cancer, not due to lack of treatment, but because it is often detected too late. AI now gives us the opportunity to identify small, incidental lung nodules early and intervene in time. At Qure.ai, I believe we are at the forefront of transforming survival outcomes within a generation.”
With over three decades of experience as a physician, academic leader, and pioneer in interventional pulmonology, Dr. Zulueta has significantly contributed to early lung cancer detection. At Spain’s Clínica Universidad de Navarra, he founded the Department of Respiratory Medicine and led the nation’s first lung cancer screening program as part of the International Early Lung Cancer Action Program (IELCAP). He has also served in advisory roles with global medtech companies.
This leadership addition comes as Qure.ai accelerates its growth in the US. Earlier in 2025, the company appointed Jim Mercadante as Chief Commercial Officer and expanded its business development and strategic accounts teams. Recently, Qure.ai was named a TIME100 Most Influential Company 2025 for its pioneering use of AI in diagnosing and improving access to care for high-burden diseases. The company’s solutions are deployed in more than 100 countries and include 18 FDA-cleared findings.